Xeris Pharmaceuticals’ Hypoglycemia Drug Nabs EU Authorization

Xeris Pharmaceuticals has won approval in Europe for Ogluo (glucagon), an injectable treatment for severe hypoglycemia in adults, teenagers and children over two years old.

The approval was supported by a phase 3 study in 132 adults with type 1 diabetes, in which Ogluo showed comparable efficacy to Novo Nordisk’s glucagon injection.

Xeris plans to launch the drug in Europe this year in collaboration with a partner, according to Paul R. Edick, the company’s CEO and chairman.